
TARA Stock Forecast & Price Target
TARA Analyst Ratings
Bulls say
Protara Therapeutics Inc. is demonstrating substantial advancements in its therapeutic programs, particularly with TARA-002, which has shown a notable improvement in efficacy profiles over time, marked by 100% durability and an 80% salvage rate upon re-induction. Additionally, the company's intravenous choline chloride has exhibited significant liver health improvements in Phase 2 trials, outperforming placebo in managing intestinal failure associated liver disease (IFALD). With the potential for competitive efficacy, a strong safety profile, and flexible pricing strategies, Protara is well-positioned to enhance its market presence and achieve widespread adoption of its innovative treatments.
Bears say
Protara Therapeutics reported a significant net loss of $12.7 million in the fourth quarter of 2024, reflecting financial challenges despite its promising therapies. The company’s lead program, TARA-002, shows potential in treating non-muscle invasive bladder cancer (NMIBC), yet the competitive landscape could hinder its market acceptance, compounded by supply issues related to essential adjunct therapies. Additionally, concerns surrounding the effectiveness of intravenous choline chloride as a treatment for intestinal failure associated liver disease further contribute to the negative outlook, particularly in light of observed liver damage linked to dietary choline depletion.
This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TARA Analyst Forecast & Price Prediction
Start investing in TARA
Order type
Buy in
Order amount
Est. shares
0 shares